Nasdaq · CIK 0001658247 · PHARMACEUTICAL PREPARATIONS
Crinetics Pharmaceuticals, Inc.
CRNX chart by TradingView
PRICE HISTORY
LIVE · NASDAQCRNX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-0.5B
- FREE CASH FLOW
- $-0.4B
- EPS
- $-4.95
- GROSS MARGIN
- 86.02%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 29 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
93.7x
-93%93.7x4108.7x
⤢
P / BOOK
3.3x
-20%2.3x4.9x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-10.76%
-1.8pp-16.63%-5.08%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
+2919%⤢
EBITDA (DERIVED)
$-0.1B
$0.1B⤢
NET INCOME
$-0.1B
$0.1B⤢
EPS (DILUTED)
$-1.14
$0.42⤢
REVENUE GROWTH YOY
2336.28%
+2353.2pp-100.00%2873.41%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-377.08%
+7.5pp-78028.67%-377.08%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-42.08%
-29.5pp-72.36%-12.54%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN99.39%
OPERATING MARGIN-527.35%
NET MARGIN-481.15%
FCF MARGIN-377.08%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.1B
$0.1B⤢
STOCK-BASED COMP
$0.0B
+33984%⤢
CAPITAL EXPENDITURE
$0.0B
+2794%⤢
SHARES OUTSTANDING
0.11B
+176%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.1B
-19%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 122.85%INSIDERS 1.55%OTHER / RETAIL 0.00%380 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 14.86% | 15.8M | $1.33B | +10.3% |
| Blackrock Inc. | 7.99% | 8.5M | $712.9M | +6.1% |
| Farallon Capital Management LLC | 7.86% | 8.3M | $701.1M | NEW |
| Wellington Management Group, LLP | 7.69% | 8.2M | $685.9M | +1.5% |
| Driehaus Capital Management, LLC | 6.03% | 6.4M | $537.8M | +0.1% |
| Price (T.Rowe) Associates Inc | 5.05% | 5.4M | $450.3M | +2.5% |
| Vanguard Capital Management LLC | 4.41% | 4.7M | $393.0M | NEW |
| Vanguard Portfolio Management LLC | 4.37% | 4.6M | $390.0M | NEW |
| Janus Henderson Group PLC | 4.26% | 4.5M | $380.1M | +1.8% |
| EcoR1 Capital, LLC | 4.04% | 4.3M | $360.5M | +0.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.